Easton P A, Jadue C, Dhingra S, Anthonisen N R
N Engl J Med. 1986 Sep 18;315(12):735-9. doi: 10.1056/NEJM198609183151205.
We evaluated the effect of anticholinergic and beta-adrenergic inhaled bronchodilators, alone or in sequence, in 11 patients with chronic obstructive pulmonary disease. We compared the agents albuterol and ipratropium bromide when each was used as a single aerosol in the maximal dose. After giving a maximal dose of one agent, we compared the effect of adding the other with that of adding a placebo. When used alone, both bronchodilators significantly increased airflow and relieved hyperinflation, and there was no significant difference between the two. After the improvement with the initial bronchodilator, the subsequent effect of a second inhaled bronchodilator was not greater than that of placebo. These results suggest that in the treatment of chronic obstructive pulmonary disease, these two aerosols are usually equipotent in maximal doses and the addition of a second agent is of no practical value. The data support the prescription of a single inhaled agent in most cases but do not rule out the value of combinations of agents under special circumstances.
我们评估了抗胆碱能和β-肾上腺素能吸入性支气管扩张剂单独或序贯使用对11例慢性阻塞性肺疾病患者的影响。我们比较了沙丁胺醇和异丙托溴铵在最大剂量单剂使用时的效果。在给予一种药物最大剂量后,我们比较了加用另一种药物与加用安慰剂的效果。单独使用时,两种支气管扩张剂均显著增加气流并缓解肺过度充气,两者之间无显著差异。在初始支气管扩张剂改善病情后,第二种吸入性支气管扩张剂的后续效果不大于安慰剂。这些结果表明,在慢性阻塞性肺疾病的治疗中,这两种气雾剂在最大剂量时通常等效,加用第二种药物没有实际价值。数据支持在大多数情况下开具单一吸入药物的处方,但不排除在特殊情况下联合用药的价值。